KMT2D

Across TCGA pan-cancer cohorts, KMT2D mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of KMT2D’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where KMT2D mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types KMT2D is over-expressed in tumor, although a few such as HNSC and PDAC show the opposite, repressed pattern.

CCRCC, COAD, and HNSC are the cancer types where KMT2D tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KMT2D mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	III,IV	+0.186	<.001	11	view →
COAD	Male	III,IV	+0.662	<.001	10	view →
HNSC	All	All	−0.104	.003	5	view →
PDAC	All	II,III,IV	−0.192	.002	4	view →
LSCC	All	All	+0.060	.014	4	view →
LUAD	Male	All	+0.113	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

KMT2D–CCRCC

Open the CCRCC breakdown →